Literature DB >> 9571372

Recent developments in the molecular characterization of Barrett's esophagus.

R C Fitzgerald1, G Triadafilopoulos.   

Abstract

Barrett's esophagus, or specialized intestinal metaplasia, is a common condition associated with gastroesophageal reflux and an increased risk for adenocarcinoma of the esophagus and gastric cardia. Currently, clinical surveillance for early detection of adenocarcinoma relies on the histopathological assessment of dysplasia. In this review we present data from the published literature, and combine this with results from our own research, to address what is currently known about the environmental factors and the molecular changes thought to be important in the pathogenesis of Barrett's esophagus. The most important and well-characterized molecular changes, preceding the development of dysplasia, are alterations in the p53 and erbB-2 genes and aneuploidy. These molecular changes, as well as environmental influences, such as the quality and quantity of gastroduodenal refluxate, may result in abnormal cell proliferation which in turn promotes further genetic abnormalities and deregulation of cell growth. The identification of molecular changes, in the context of predisposing environmental factors, will enhance our understanding of the malignant progression of Barrett's esophagus leading to more effective surveillance and treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9571372     DOI: 10.1159/000016850

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  19 in total

1.  Barrett's oesophagus and proton pump inhibitors: a pathological perspective.

Authors:  N A Shepherd
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

2.  The pathogenesis of Barrett's esophagus: a process in continuum or discontinuum.

Authors:  R C Fitzgerald; M J Farthing
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 3.  Barrett's esophagus with high-grade dysplasia: focus on current treatment options.

Authors:  Leonidas Lekakos; Nikolaos P Karidis; Dimitrios Dimitroulis; Christos Tsigris; Gregory Kouraklis; Nikolaos Nikiteas
Journal:  World J Gastroenterol       Date:  2011-10-07       Impact factor: 5.742

4.  Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.

Authors:  Rebecca E Rudolph; Thomas L Vaughan; Alan R Kristal; Patricia L Blount; Douglas S Levine; Patricia C Galipeau; Laura J Prevo; Carissa A Sanchez; Peter S Rabinovitch; Brian J Reid
Journal:  J Natl Cancer Inst       Date:  2003-05-21       Impact factor: 13.506

5.  Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus.

Authors:  S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 6.  Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

Authors:  Panagiotis Tsibouris; Erasmia Vlachou; Peter Edward Thomas Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

Review 7.  Biomarkers and the genetics of early neoplastic lesions.

Authors:  Sudhir Srivastava; William E Grizzle
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

8.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

9.  Inflammatory gradient in Barrett's oesophagus: implications for disease complications.

Authors:  R C Fitzgerald; S Abdalla; B A Onwuegbusi; P Sirieix; I T Saeed; W R Burnham; M J G Farthing
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

10.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.